11.33 -0.05 (-0.44%) | 07-18 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 13.5 ![]() |
1-year : | 15.77 ![]() |
Resists | First : | 11.56 ![]() |
Second : | 13.5 ![]() |
Pivot price | 10.35 ![]() |
|||
Supports | First : | 9.37 ![]() |
Second : | 8.02 |
MAs | MA(5) : | 11.26 ![]() |
MA(20) : | 9.98 ![]() |
MA(100) : | 8.08 ![]() |
MA(250) : | 8.55 ![]() |
|
MACD | MACD : | 0.7 ![]() |
Signal : | 0.6 ![]() |
%K %D | K(14,3) : | 92.2 ![]() |
D(3) : | 91.9 ![]() |
RSI | RSI(14): 75.2 ![]() |
|||
52-week | High : | 11.77 | Low : | 5.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OCUL ] has closed below upper band by 22.2%. Bollinger Bands are 74.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 11.57 - 11.63 | 11.63 - 11.69 |
Low: | 11.09 - 11.16 | 11.16 - 11.21 |
Close: | 11.22 - 11.33 | 11.33 - 11.43 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Wed, 09 Jul 2025
Ocular Therapeutix(OCUL) Soars 8.47% on Pipeline Progress - AInvest
Thu, 26 Jun 2025
Ocular Therapeutix Launches New Corporate Branding to Enhance Retina-Focused Mission - Nasdaq
Thu, 26 Jun 2025
Ocular Therapeutix Pivots to $14B Retina Market with Revolutionary AMD Treatment Platform - Stock Titan
Thu, 26 Jun 2025
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - GlobeNewswire
Wed, 25 Jun 2025
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 159 (M) |
Shares Float | 122 (M) |
Held by Insiders | 3.8 (%) |
Held by Institutions | 87 (%) |
Shares Short | 14,420 (K) |
Shares Short P.Month | 13,830 (K) |
EPS | -1.12 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.66 |
Profit Margin | 0 % |
Operating Margin | -597.5 % |
Return on Assets (ttm) | -27.3 % |
Return on Equity (ttm) | -57.2 % |
Qtrly Rev. Growth | -27.7 % |
Gross Profit (p.s.) | -0.61 |
Sales Per Share | 0.37 |
EBITDA (p.s.) | -1.27 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -145 (M) |
Levered Free Cash Flow | -88 (M) |
PE Ratio | -10.21 |
PEG Ratio | 0 |
Price to Book value | 6.78 |
Price to Sales | 30.25 |
Price to Cash Flow | -12.41 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |